Dr. James John Ignatz-Hoover, MD, PhD

Dr. Ignatz-Hoover practices at University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System.

Dr. Ignatz-Hoover's NPI, 1679076442, was assigned on March 17, 2018. Dr. Ignatz-Hoover graduated from Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University in 2018. Dr. Ignatz-Hoover holds Ohio license 35.142751.

Dr. Ignatz-Hoover's primary practice is University Hospitals Cleveland Medical Center, at 11100 Euclid Avenue, Cleveland, OH 44106 in Cuyahoga County. The practice phone is (216) 844-1000.

Dr. Ignatz-Hoover's primary practice is University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System. Dr. Ignatz-Hoover is also affiliated with University Hospitals Parma Medical Center. The medical group on file is University Hospitals Medical Practices.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ignatz-Hoover practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Ignatz-Hoover's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Ignatz-Hoover is licensed in Ohio.

CMS data shows 112 Medicare services from Dr. Ignatz-Hoover across 4 procedure codes in 2024, for 54 Medicare patients. Medicare paid $10,504 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 54 Medicare patients who saw Dr. Ignatz-Hoover in 2024. The largest group is 65 to 74, with 29 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ignatz-Hoover's median patient age at 70, with 50% women.

In 2024, Dr. Ignatz-Hoover wrote 153 Medicare Part D claims for 20 patients. 76% of them were for generic drugs. CMS names the drug for 100 of them, across 5 drugs with 11 or more claims each, at $597,011 in total drug cost. In 2019, CMS named 58 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Ignatz-Hoover for performance year 2024, reported as part of a group. Dr. Ignatz-Hoover accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ignatz-Hoover as offering telehealth.

Dmand AI links 14 papers to Dr. Ignatz-Hoover, published from 2014 to 2025. 2022 was the busiest year, with 3. The most frequent topics are Multiple Myeloma, Cell Line, Tumor and Proteasome Endopeptidase Complex. Dr. Ignatz-Hoover has published most often in Cancers (Basel). Dr. Ignatz-Hoover's most frequent co-authors are James Joseph Driscoll, MD, Brenda W. Cooper, MD and Marcos Jose Garcia De Lima, MD.

CMS Open Payments shows 67 general payments to Dr. Ignatz-Hoover from 30 drug and device companies from 2021 to 2025. Speaker and faculty fees make up the largest share, 44% of the total. Sanofi and Genzyme US Companies paid the most, $4,532.

Dr. Ignatz-Hoover graduated from Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University in 2018.